Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Breast Cancer Genetics, Immunology, and Immunotherapy: An Interdisciplinary Approach / / edited by Nima Rezaei
| Breast Cancer Genetics, Immunology, and Immunotherapy: An Interdisciplinary Approach / / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2024.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (436 pages) |
| Disciplina |
571.978
616.994 |
| Collana | Interdisciplinary Cancer Research |
| Soggetto topico |
Cancer
Cancer - Treatment Cancer - Genetic aspects Oncology Tumors - Immunological aspects Immunotherapy Cancer Biology Cancer Therapy Cancer Genetics and Genomics Tumour Immunology |
| ISBN |
9783031658082
9783031658075 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Role of miRNAs in Triple-Negative Breast Cancer: Diagnosis, Prognosis, and Treatment -- Approaches to Breast Cancer Immunology and Immunotherapy -- Molecular Genetics of Breast Cancer: From Mechanistic Insights to the Therapeutic Approaches -- Interleukins in the Development and Progression of Breast Cancer -- Shaping of the Immune Landscape by Chemokine Receptors that Impacts the Clinical Outcome in Triple-Negative Breast Cancer -- The Prognostic Impact of Tumor-Infiltrated Lymphocytes (TILs) in Breast Cancer -- From Genes to Recovery: Precision Medicine and Its Influence on Multidrug Resistant Breast Cancer -- Recent Progress and Prospects of Immunotherapy in Multidrug-Resistant and Metastatic Breast Cancer Treatment -- Targeting Myeloid Determinants of Breast Cancer -- siRNA Loaded in Drug Delivery Nanosystems as a Strategy for Breast Cancer Treatment -- Nucleic Acid and Drug Dual Agent Nanoplatforms for Breast Cancer -- Oncolytic Virotherapy Against Breast Cancer -- Overcoming Breast Cancer Resistance to Targeted, Chemo-, and Immuno Therapy: Mechanisms and Strategies to Overcome Resistance and Facilitate Drug Development. |
| Record Nr. | UNINA-9910874677603321 |
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Breast Cancer Treatment : an interdisciplinary approach / / Nima Rezaei, editor
| Breast Cancer Treatment : an interdisciplinary approach / / Nima Rezaei, editor |
| Autore | Rezaei Nima |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing AG, , 2024 |
| Descrizione fisica | 1 online resource (445 pages) |
| Collana | Interdisciplinary Cancer Research Series |
| Soggetto topico | Breast Neoplasms - therapy |
| ISBN |
9783031658273
9783031658266 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- About the Editor -- Signal Transducer and Activator of Transcription as a Potential Therapeutic Target in Breast Cancer -- 1 Introduction -- 2 STAT Family Members Characteristics, Activation, and Functional Development -- 2.1 STAT Family Members Expression and Activity in Breast Cancer -- 2.2 STAT1 and Breast Cancer -- 2.3 STAT2 and Breast Cancer -- 2.4 STAT3 and Breast Cancer -- 2.5 STAT4 and Breast Cancer -- 2.6 STAT5a/b and Breast Cancer -- 2.7 STAT6 and Breast Cancer -- 2.8 ER+ Breast Cancer Subtypes and STAT Signaling -- 2.9 HER2/Neu + Breast Cancer and STAT Signaling -- 2.10 TNBC and STAT Signaling -- 3 STAT Proteins: The Promising Targets in the Treatment of Breast Cancer -- 4 Conclusion -- References -- Triple-Negative Breast Cancer Therapy: Recent Advances, Challenges, and Future Perspective -- 1 Introduction -- 2 Predictive Biomarkers, TILs, Genes and Their Roles in TNBC -- 3 Drug Resistance in TNBC -- 4 Systemic Therapy in TNBC -- 5 siRNA Therapy in TNBC -- 6 Conclusion -- References -- Advances in Local Ablative Techniques for Breast Cancer -- 1 Introduction -- 2 Overview of Local Ablative Techniques in Breast Cancer Management -- 3 Localization Techniques -- 4 Ablative Treatment Modalities for Curative Intent -- 4.1 Cryotherapy -- 4.2 Radiofrequency Ablation (RFA) in Breast Cancer Management -- 4.3 High-Intensity Focused Ultrasound (HIFU) -- 4.4 Microwave Ablation -- 4.5 Laser Therapy in Breast Cancer Management -- 5 Ablative Surgery in Palliative Settings -- 5.1 Local Therapy -- 5.2 Ablative Therapies Toward Metastatic Lesion(s) -- 5.2.1 Bone -- 5.2.2 Liver -- 5.2.3 Lung -- 5.2.4 Others -- 6 Conclusion -- References -- Radiotherapy in Breast Cancer -- 1 Introduction -- 2 History -- 3 Overview of Breast Cancer -- 3.1 Types -- 3.2 Breast Cancer Subtypes -- 3.2.1 Hormone Receptor-Positive Breast Cancer.
3.2.2 HER2-Positive Breast Cancer -- 3.2.3 Triple-Negative Breast Cancer -- 3.3 Risk Factors and Etiology -- 3.4 Pathophysiology -- 3.5 Signs and Symptoms -- 3.6 Diagnosis -- 3.7 Staging -- 3.8 Prognosis -- 4 Types of Radiation Therapy -- 5 Uses of Radiotherapy in Breast Cancer -- 6 Brachytherapy -- 7 Combination Therapy and Management of Breast Cancer -- 7.1 Chemotherapy -- 7.2 Targeted Therapy -- 7.3 Management of Non-invasive (In Situ) Breast Cancer -- 7.4 Management of Early Invasive Breast Cancer -- 7.5 Loco-Regional Radiotherapy -- 7.6 Axillary Radiotherapy -- 8 Adverse Effects of Radiation Therapy -- 9 Conclusion -- References -- Percutaneous Breast Cancer Treatment -- 1 Introduction -- 2 Cryoablation -- 3 Radiofrequency Ablation -- 4 Microwave Ablation -- 5 High-Intensity Focused Ultrasound (HIFU) -- 6 Laser Ablation -- 7 Conclusion -- References -- Revolutionizing Breast Cancer Care: Cutting-Edge Breakthroughs and Future Frontiers in Precision Medicine -- 1 Introduction -- 2 Targeted Therapies -- 2.1 Hormone Receptor-Targeted Therapies -- 2.2 HER2-Targeted Therapies -- 2.3 Cell Cycle-Targeted Therapies -- 3 Immunotherapy -- 3.1 Immune Checkpoint Inhibitors -- 3.2 Cancer Vaccines -- 4 Precision Medicine -- 5 Other Emerging Therapies -- 5.1 Oncolytic Viruses -- 5.2 PARP Inhibitors -- 6 Personalized Treatment Approaches -- 6.1 Integration of Genomic and Clinical Data -- 6.2 Development of Decision Support Tools -- 7 Nanotechnology in Breast Cancer Treatment -- 7.1 Folic Acid-Engineered Nanocarriers -- 7.2 Antineoplastic Biogenic Gold Nanoparticles -- 7.3 Lipid-Based Nanoparticles (LNPs) -- 7.4 Curcumin Nanoparticles -- 7.5 Antibody-Conjugated Polymeric Nanoparticles -- 8 Other Treatment Strategies -- 8.1 Liquid Biopsies -- 8.2 Artificial Intelligence -- 9 Role of Modern Bioinformatics in the Treatment of Breast Cancer. 10 Role of CRISPR Gene Editing in Treating Breast Cancer -- 11 Conclusion -- References -- Updates on the Management of Ductal Carcinoma In Situ of the Breasts -- 1 Introduction -- 2 Breast Cancer Screening and Diagnosis of DCIS -- 3 Classification Systems of DCIS -- 4 Challenges in Histopathological Diagnosis -- 5 Paradigm Change of the Current Standard of Care -- 6 Treating DCIS or Treating Patients with DCIS? -- 7 Clinical Factors to Be Considered When Treating Low-Risk DCIS -- 8 Conclusion -- References -- Nanostructured Lipid Carrier as a Strategy for the Treatment of Breast Cancer -- 1 Introduction -- 2 Conventional Treatment of Breast Cancer -- 2.1 Lipidic Nanoparticle as a Strategy for the Treatment of Breast Cancer -- 2.2 Nanostructured Lipid Carriers as a Strategy for the Treatment of Breast Cancer -- 3 Cancer Drug-Loaded NLC -- 3.1 Anthracycline-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.2 Taxane-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.3 Antagonist of Estrogen Receptor-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.4 HIT, LEAD, or Drug Candidate-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.5 Multidrug-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.6 Developing Theory -- 3.7 Stimuli-Responsive NLC as a Strategy for the Treatment of Breast Cancer -- 4 New Trends: Functionalized CLN -- 5 Conclusion -- References -- Managing Breast Cancer Using the Cell-Surface GRP78 -- 1 Introduction -- 1.1 Targeting GRP78 for Early Detection and Diagnosis -- 1.2 Modulating GRP78 Expression for Therapeutic Intervention -- 1.3 GRP78 as a Prognostic Indicator and Monitoring Tool -- 1.4 GRP78 Mediates Cell Survival and Apoptosis -- 1.5 Challenges and Future Prospects -- 2 Conclusion -- References. A Hormone Immunotherapy (HIT) Combination in Advanced Breast Cancer -- 1 Introduction -- 2 Current Guidelines for HT, IT, and Their Combination in Advanced Breast Cancer -- 2.1 Systemic Therapy in the Adjuvant Setting (Table 1) -- 2.2 Systemic Therapy in Locoregional Recurrent or Stage IV (M1) Breast Cancer (Table 2) -- 3 Experimental Studies Suggest a Close Relationship Between Tumor Growth and the G0-G1 State and Immune Evasion -- 3.1 Tumor Growth and Immune Evasion -- 3.2 G0-G1 State and Immunosuppressive TME Reversion Induced by Antiestrogens -- 4 Usefulness of Maintenance IT in Patients Showing Clinical Benefit During Conventional CT or with Minimal Residual Disease (M... -- 5 A Prolonged Antiestrogen-Induced G0-G1 State Concomitant with an Increased Cytotoxic Immune Response During a New Schedule o... -- 6 The Potential Rationale of a New HIT Schedule -- 7 Conclusion -- References -- Discovering New Targets in Triple-Negative Breast Cancer (TNBC): The Androgen Receptor and the Estrogen Receptor β -- 1 Introduction -- 2 Triple-Negative Breast Cancer -- 2.1 TNBC Therapies -- 2.2 Targeted Therapies -- 2.3 Immunotherapy -- 2.4 AR in Triple-Negative Breast Cancer -- 2.4.1 AR: Structure and Function -- 2.4.2 AR in Breast Cancer: An Overview -- 2.4.3 The Role of AR in TNBC -- 2.4.4 Androgen Targeted Therapies -- 2.5 Estrogen Receptor β in Triple-Negative Breast Cancer -- 2.5.1 Estrogen Receptor β: Generalities -- 2.5.2 The Role of ERβ in BC: An Overview -- 2.5.3 The Role of ERβ in Triple-Negative Breast Cancer -- 2.5.4 Estrogen Receptor β Targeted Therapy in TNBC -- 3 Concluding Remarks -- References -- Growth Factor Receptor Implications in Breast Cancer: Prospects for Their Molecular Transactivation in the Future and Obstacle... -- 1 Introduction -- 1.1 Incidence -- 1.2 Risk Factors -- 2 Definition and Molecular Classification of BC. 2.1 BC Classification -- 2.2 Histological Subtypes -- 2.3 Molecular Subtypes -- 2.4 Estrogen Receptor (ER) -- 2.5 Nuclear ER -- 2.6 Membranal ER -- 2.7 Relationship Between ER and HER2 -- 3 Receptor Tyrosine Kinases -- 3.1 Structure and Classification -- 3.2 Role of Receptor Tyrosine Kinase (RTK) Signaling in BC Progression: MAPKs and PI3K/Akt Signaling Pathways -- 3.2.1 Signaling Pathways -- 3.2.2 Mitogen-Activated Protein Kinase Pathway (MAPK) -- 3.2.3 ERK Cascade -- 3.2.4 JNK Cascade -- 3.2.5 p38 Cascade -- 3.2.6 Phosphoinositide 3-Kinase/Akt Pathway (PI3K/Akt) -- 3.2.7 Janus Kinase/Signal Transducer and Activator of Transcription Pathway (JAK/STAT) -- 3.2.8 Notch Signaling Pathway -- 3.2.9 Nuclear Factor-Kappa B Pathway (NF-κB) -- 3.2.10 Src Family Kinases -- 4 Participation of Specific RTKs in BC -- 4.1 RTKs and BC -- 4.2 Role of Epidermal Growth Factor Receptor (EGFR) in BC -- 4.3 Role of HER2 in BC -- 4.4 Role of Insulin Receptor (IR) in BC -- 4.5 Role of Insulin-Like Growth Factor Receptor Type 1 (IGF-1R) in BC -- 4.6 Role of Vascular Endothelial Growth Factor Receptor (VEGR) in BC -- 4.7 Role of Platelet-Derived Growth Factor Receptor (PDGFR) in BC -- 4.8 Role of Fibroblast Growth Factor Receptor (FGFR) in BC -- 4.9 Role of Hepatocyte Growth Factor (HGF)/MET Receptor in BC -- 5 RTK Transactivation by GPCRS and Nuclear Receptors -- 5.1 GPCRs -- 5.2 GPCR-Mediated Transactivation of RTKs -- 5.3 GPCRS in Cancer and BC -- 5.4 RTK Transactivation by Specific GPCRs in BC -- 5.4.1 Estrogens/GPER1 -- 5.4.2 Chemokine Receptors -- 5.4.3 Cannabinoid Receptor 2 -- 5.4.4 Lysophosphatidic Acid (LPA) Receptors (LPARs) -- 5.4.5 Protease-Activated Receptors -- 6 Blocking GPCRS-RTKs Transactivation, Therapeutic Strategies with a Clinical Approach -- References -- Addressing ESR1 Mutation: A Key Factor in Hormone Therapy Resistance in Breast Cancer. 1 Introduction. |
| Record Nr. | UNINA-9910874667903321 |
|
Rezaei Nima
|
||
| Cham : , : Springer International Publishing AG, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer and Surrounding Environment : Etiologies and Tumor Microenvironment / / edited by Nima Rezaei
| Cancer and Surrounding Environment : Etiologies and Tumor Microenvironment / / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2025.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 |
| Descrizione fisica | 1 online resource (1195 pages) |
| Disciplina | 616.994071 |
| Collana | Handbook of Cancer and Immunology |
| Soggetto topico |
Cancer
Immunology Immunotherapy Tumors - Immunological aspects Cancer - Treatment Cancer Biology Tumour Immunology Cancer Therapy |
| ISBN | 3-032-00761-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction to Tumor Microenvironment -- Tertiary Lymphoid Structure Formation and Function in the Tumor Microenvironment -- Role of Immune Cells in the Tumor Microenvironment -- Advances in Tumor Microenvironment Immune Profiling -- Angiogenesis and the Tumor Microenvironment -- Tumor Microenvironment Complexity A Pathological Milieu that Innately Modulates Cancer Progression -- Macrophage Polarization in the Tumor Microenvironment Modulation and Mimicry -- Neuroimmune Crosstalk in the Tumor Microenvironment -- Role of C Type Lectins in the Tumor Microenvironment -- Spatial Technologies A Game Changer for Studying the Tumor Microenvironment. |
| Record Nr. | UNINA-9911031639303321 |
|
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer and Targeting the Immune System : Tumor Vaccines and Immunotherapy / / edited by Nima Rezaei
| Cancer and Targeting the Immune System : Tumor Vaccines and Immunotherapy / / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2025.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 |
| Descrizione fisica | 1 online resource (1359 pages) |
| Disciplina | 616.99406 |
| Collana | Handbook of Cancer and Immunology |
| Soggetto topico |
Cancer
Immunology Immunotherapy Tumors - Immunological aspects Cancer - Treatment Cancer Biology Tumour Immunology Cancer Therapy |
| ISBN | 3-032-00767-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction on Cancer Immunotherapy -- Natural Human Immune Response Identifies An Unnatural Oncology Target for Immunotherapy -- Adoptive Immunotherapy Is a Successful Step into Bright Future -- Cancer Immunotherapy Clinical Trials -- Preclinical Cancer Models for the Evaluation of Immunotherapies From Cell Lines to Animal Models -- Immunotherapy and Cancer The Pharmacists Perspective -- Turning Cold into Hot New Insights in Cancer Immunotherapy -- Emerging Trends in Monoclonal Antibody Therapies Targeting Cancer -- Bispecific Antibodies in Targeted Cancer Immunotherapy -- T-Cell Based Therapies Clinical Applications and Challenges. |
| Record Nr. | UNINA-9911031631503321 |
|
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer Challenges : Tumor Prevention, Prognosis, and Adverse Effects of Immunotherapy / / edited by Nima Rezaei
| Cancer Challenges : Tumor Prevention, Prognosis, and Adverse Effects of Immunotherapy / / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2025.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 |
| Descrizione fisica | 1 online resource (1390 pages) |
| Disciplina | 616.994061 |
| Collana | Handbook of Cancer and Immunology |
| Soggetto topico |
Cancer
Immunology Immunotherapy Tumors - Immunological aspects Cancer - Treatment Cancer Biology Tumour Immunology Cancer Therapy |
| ISBN | 3-032-00775-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction on Cancer Modifiable Risk Factors and Prevention -- Cancer Epidemiology and Prevention -- Health Crisis and Cancer Prevention Friend or Foe -- Cancer A Major Public Health Issue Associated with Occupational Environment and Safety -- Blood-Based Cancer Screening Early Cancer Detection -- Circulating Tumor Cells in the Early Detection of Human Cancers -- Role of Tumor Markers in Early Detection and Prevention of Complications in Oncology -- Cancer Prognosis in Brief -- Global HPV Vaccination Post-pandemic -- The Role of HPV in Head and Neck Cancer. |
| Record Nr. | UNINA-9911031637603321 |
|
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer Diagnosis : Tumor Immunodiagnostic Tests / / edited by Nima Rezaei
| Cancer Diagnosis : Tumor Immunodiagnostic Tests / / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2025.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 |
| Descrizione fisica | 1 online resource (1162 pages) |
| Disciplina | 616.9940756 |
| Collana | Handbook of Cancer and Immunology |
| Soggetto topico |
Cancer
Immunology Immunotherapy Tumors - Immunological aspects Cancer - Treatment Cancer Biology Tumour Immunology Cancer Therapy |
| ISBN | 3-032-00763-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction on Cancer Immunodiagnosis -- Immunodiagnostics A Perspective on Sensitivity, Specificity, and Stability of Tumor Antigens -- Immunohistochemistry and Molecular Biology of Cancer -- Immunohistochemistry in the Diagnosis of Primary and Secondary Cancers -- Biomarkers for Monitoring the Immunotherapy Response to Cancer -- Predictive and On Treatment Monitoring Role of Circulating Biomarkers in Immuno-oncology -- Autoantibodies as Diagnostic Cancer Biomarkers -- Proteomics and Protein Biomarkers in Cancer Metastasis -- Role of Cyclin-Dependent Kinase Inhibitors (CKIs) as a Prognostic Biomarker for Cancer -- Single-Cell Sequencing in Cancer Research Challenges and Opportunities. |
| Record Nr. | UNINA-9911031632603321 |
|
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer Immunoediting : Immune Checkpoints and Targeting for Treatment of Tumors / / edited by Nima Rezaei
| Cancer Immunoediting : Immune Checkpoints and Targeting for Treatment of Tumors / / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2025.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 |
| Descrizione fisica | 1 online resource (878 pages) |
| Disciplina | 616.994061 |
| Collana | Handbook of Cancer and Immunology |
| Soggetto topico |
Cancer
Immunology Immunotherapy Tumors - Immunological aspects Cancer - Treatment Cancer Biology Tumour Immunology Cancer Therapy |
| ISBN | 3-032-00765-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction on Immune Checkpoints in Cancer -- Immune Checkpoint Blockade Response Biomarkers -- Immune Checkpoint Therapy A New Opportunity for Cancer Treatment -- Immune Checkpoint Inhibitors and Anti-Angiogenic Therapy for Cancer -- The Role of Soluble Immune Checkpoints in Cancer Immunotherapy -- T-Cell Metabolism and Its Regulation by Checkpoint Molecules Consequences for Cancer Immunotherapy -- Biomarkers of Prediction of Immunotherapy and Updates on CTLA 4 Therapy -- Assessing PD L1 Expression in Different Tumor Types -- Imaging Correlates of Immune Checkpoint Inhibitors in Cancer Management -- RadiationInduced Immunoediting of Cancer. |
| Record Nr. | UNINA-9911031637103321 |
|
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer Immunology : The Immune System and Tumor / / edited by Nima Rezaei
| Cancer Immunology : The Immune System and Tumor / / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2025.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 |
| Descrizione fisica | 1 online resource (1173 pages) |
| Disciplina |
571.978
616.994 |
| Collana | Handbook of Cancer and Immunology |
| Soggetto topico |
Cancer
Immunology Immunotherapy Tumors - Immunological aspects Cancer - Treatment Cancer Biology Tumour Immunology Cancer Therapy |
| ISBN | 3-032-00749-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction to Cancer Immunology -- Cancer Immunotherapy From Ancient Intuitive Practices to Scientific Breakthroughs and Nobel Prize -- Cancer and Immunology The Homeostasis Dance -- Cancer Initiation and Inflammation -- B Cells and Antibody Production in Cancer -- TCell Exhaustion in Cancers -- The Role of Innate T Cells in Cancer -- Role of T Helper 17 in Cancer Pathology A Double-Edge Sword -- Regulatory Cell Subset Responses in Cancerous Diseases Pathophysiological and Clinical Challenges -- The Role of Gamma Delta T Cells in Cancer. |
| Record Nr. | UNINA-9911031630103321 |
|
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer Immunology and Genetics: An Interdisciplinary Approach / / edited by Nima Rezaei
| Cancer Immunology and Genetics: An Interdisciplinary Approach / / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2025.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 |
| Descrizione fisica | 1 online resource (1222 pages) |
| Disciplina |
571.978
616.994 |
| Collana | Interdisciplinary Cancer Research |
| Soggetto topico |
Cancer
Cancer - Treatment Oncology Immunotherapy Tumors - Immunological aspects Nanomedicine Cancer Biology Cancer Therapy Tumour Immunology Cancer Nanotechnology |
| ISBN | 3-031-99374-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Thymic Stromal Lymphopoietin and Malignancies -- Immunogenic Cancer Cell Death -- Epigenetics in Cancer Biology -- Microenvironment of Normal Looking Tissues Adjacent to Cancer: Matters Arising -- The Paradoxical Role of Immune Response in Cancer Microenvironment -- T Cells and Their Roles in Tumor Microenvironments -- Role of Regulatory Immune Cells in Tumour Microenvironment (TME) -- Exploring the Metabolic Reprogramming of Immune Cells in Tumor Microenvironments -- Innate Lymphoid Cells in Cancer Immunobiology and Immunotherapy -- Tumor-Associated Macrophages and Their Role in Cancer Progression and Treatment Strategies -- Tumor-associated Macrophages in Colorectal Cancer -- Impact of Siglec-Sialic Acid Axis on the Cancer Immune Response -- Mechanisms on Telomere Maintenance in Cancer Cells -- Classification of SNPs, Tips from the Basic Knowledge to the Clinical Outcomes -- The Potential Role of HLA-G on Cancer -- Two Sides of the Same Coin: Genes Involvement in Neurodegeneration and Cancer -- MicroRNA: Exploring Their Multifaceted Role in Cancer -- Role of miRNAs in cancer: Main Therapeutic, Diagnostic, and Oncogenic Features -- LncRNA: Secret Regulators of Cancer Metabolism -- Structure and Function of The H19 Long Non-Coding RNA in Cancer -- Genome Editing: Current Approaches and the Road Ahead in Cancer Research and Therapeutics -- Targeting Epigenetic Readers Using Small Molecule Binders and PROTAC Degraders -- Pharmacogenomics of Cancer Chemotherapy: Transporter Polymorphisms and Drug Response -- Genetic Variants Associated with Morphine Treatment in Cancer. |
| Record Nr. | UNINA-9911018746303321 |
|
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer Immunotherapy and Nanobiotechnology: An Interdisciplinary Approach / / edited by Nima Rezaei
| Cancer Immunotherapy and Nanobiotechnology: An Interdisciplinary Approach / / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2025.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 |
| Descrizione fisica | 1 online resource (1318 pages) |
| Disciplina |
571.978
616.994 |
| Collana | Interdisciplinary Cancer Research |
| Soggetto topico |
Cancer
Cancer - Treatment Stem cells Cytology Medical genetics Immunology Cancer Biology Cancer Therapy Cancer Stem Cells Cell Biology Medical Genetics |
| ISBN | 3-032-03862-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Targeting Mitochondria in Cancer Immunotherapy; Promises and Pitfalls -- Immunotherapy in Oncology: A Comprehensive Overview from a Pathological Perspective -- Cancer Treatments through Immunological Pathways: A Great Hope for Every Cancer Type and Every Patient? -- Cancer Immunotherapies Targeting Cancer Stem Cells: Concepts, Applications, and Advances -- Immune Checkpoint Inhibitors: Novel Therapies and Targets -- Advancing Cancer Immune Cell Therapies via Engineered iPSC-based Strategies -- CAR NK/CAR T cells: Emerging Immunotherapy of Cancer -- Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Therapy and Coagulopathies -- The Power of Imaging Techniques in CAR T-Cell Therapy Enhancement: Revolutionizing Cancer Treatment -- Discovery of T cell Epitopes for Cancer Immunotherapy -- Dendritic Cells in Cancer Immunotherapy: Current State and Future Prospects -- Tumor Microenvironment Role in Cancer Immunotherapy Response -- T-cell Responses During Cancer Immunotherapy Through the Use of CT, MRI, and PET -- Nanotechnology for Cancer Research (Diagnosis & Therapy): Recent Progress and Future Prospects -- Nanotechnology and Cancer Therapy Strategies -- Nanomedicine based Cancer Immunotherapy -- Applications of Nanocarrier Systems in Cancer Treatment -- Nanoformulations in Cancer Theranostics -- The Role of Noble Metal Nanomaterials in Cancer Therapy -- Synthetic and Natural Drug Nanodelivery Systems Used in Oncology Treatment -- Nanoparticles Loaded with Cytotoxic Agents: A Therapeutic Alternative against Cancer -- Advancements in Nanocarrier-Mediated Drug Delivery: Precision Strategies for Targeted Therapeutics and Improved Treatment Outcomes -- Vesicular Nanosystem as a Promising Platform for the Management of Cancer -- Nanoscale Metal-Organic Frameworks for Cancer-Targeted Therapy and Molecular Imaging -- Theranostic Properties of Iron Oxide Nanoparticles and Their Reprograming Properties on Tumor-associated Macrophages -- Composition of Proapoptotic Montmorillonite-Cytochrome C Nanoplates with High Anticancer Cytotoxicity: Monolayer Adsorption Approach -- Nanomaterials as Modulators of Non-apoptotic Regulated Cell Death Modes: Novel Options in Cancer Treatment. |
| Record Nr. | UNINA-9911021141303321 |
|
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
